ROIVANT SCIENCES LTD. Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
ROIVANT SCIENCES LTD. (ROIV) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of -$290.60 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-08-06
- ROIVANT SCIENCES LTD. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$290.60M.
- ROIVANT SCIENCES LTD. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was $355.74M.
- ROIVANT SCIENCES LTD. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$313.70M.
- ROIVANT SCIENCES LTD. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$166.04M.
- ROIVANT SCIENCES LTD. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2026 was -$397.91M.
- ROIVANT SCIENCES LTD. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2025 was -$729.76M, a 116.05% decline from fiscal 2024.
- ROIVANT SCIENCES LTD. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2024 was $4.55B.
- ROIVANT SCIENCES LTD. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2023 was -$889.07M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month as first filed | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$290.60M 10-Q · filed 2026-08-06 | $65.14M derived: sum of 2 quarters · filed 2026-08-06 | -$248.56M derived: sum of 3 quarters · filed 2026-08-06 | -$414.60M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $355.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $42.04M derived: sum of 2 quarters · filed 2026-05-20 | -$124.00M derived: sum of 3 quarters · filed 2026-05-20 | -$397.91M 10-K · filed 2026-05-20 | ||
| 2025-12-31 | -$313.70M 10-Q · filed 2026-02-06 | -$479.74M derived: sum of 2 quarters · filed 2026-02-06 | -$753.65M 10-Q · filed 2026-02-06 | -$1.01B derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-09-30 | -$166.04M 10-Q · filed 2025-11-10 | -$439.95M 10-Q · filed 2025-11-10 | -$692.31M derived: sum of 3 quarters · filed 2026-08-06 | -$901.26M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | -$273.90M 10-Q · filed 2026-08-06 | -$273.91M 10-Q · filed 2025-08-11 | -$526.27M derived: sum of 2 quarters · filed 2026-08-06 | -$735.22M derived: sum of 3 quarters · filed 2026-08-06 | -$972.06M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | -$252.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | -$461.32M derived: sum of 2 quarters · filed 2026-05-20 | -$698.16M derived: sum of 3 quarters · filed 2026-05-20 | -$729.76M 10-K · filed 2026-05-20 | ||
| 2024-12-31 | -$208.94M 10-Q · filed 2026-02-06 | -$445.79M derived: sum of 2 quarters · filed 2026-02-06 | -$477.39M 10-Q · filed 2026-02-06 | -$572.35M derived: sum of 4 quarters · filed 2026-05-20 | ||
| 2024-09-30 | -$236.84M 10-Q · filed 2025-11-10 | -$268.44M 10-Q · filed 2025-11-10 | -$363.40M derived: sum of 3 quarters · filed 2026-05-20 | $4.77B derived: sum of 4 quarters · filed 2026-05-20 | ||
| 2024-06-30 | -$31.60M 10-Q · filed 2025-08-11 | -$126.56M derived: sum of 2 quarters · filed 2026-05-20 | $5.00B derived: sum of 3 quarters · filed 2026-05-20 | $4.76B derived: sum of 4 quarters · filed 2026-05-20 | ||
| 2024-03-31 | -$94.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $5.04B derived: sum of 2 quarters · filed 2026-05-20 | $4.79B derived: sum of 3 quarters · filed 2026-05-20 | $4.55B 10-K · filed 2026-05-20 | $4.23B 10-K · filed 2024-05-30 | |
| 2023-12-31 | $5.13B 10-Q · filed 2025-02-10 | $4.89B derived: sum of 2 quarters · filed 2025-02-10 | $4.64B 10-Q · filed 2025-02-10 | |||
| 2023-09-30 | -$244.64M 10-Q · filed 2024-11-12 | -$489.87M 10-Q · filed 2024-11-12 | ||||
| 2023-03-31 | -$889.07M 10-K · filed 2025-05-29 | -$1.23B 10-K · filed 2023-06-28 | ||||
| 2022-03-31 | -$924.12M 10-K · filed 2023-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |